Skip to main content

EMBL Ventures Closes $55M Fund

NEW YORK (GenomeWeb News) – EMBL ventures, the venture capital arm of the European Molecular Biology Laboratory, today announced the €40 million ($55 million) first close of its EMBL Technology Fund II.

The venture arm of Heidelberg, Germany-based EMBL will remain focused on investments in European biotech and medtech companies and said that it intends to commit between €2 million and €5 million per investment.

"Basic and translational research that benefits our member states and beyond is one of EMBL's missions," Iain Mattaj, Director General of EMBL, said in a statement. "Through EMBL Ventures we will continue to leverage the network and scientific excellence of EMBL as Europe's flagship research institute to achieve this goal."

EMBL Ventures currently manages €66 million on behalf of private and institutional investors in Europe.

Filed under

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.